Medindia

X

DRAXIS to Report Fourth Quarter and Year End 2007 Results on February 7th

Friday, February 1, 2008 General News J E 4
Advertisement
MONTREAL, Jan. 31 /PRNewswire-FirstCall/ - DRAXIS Health Inc. (TSX: DAX)(Nasdaq: DRAX) will report financial and operating results for its FourthQuarter and Year End 2007 on Thursday February 7, 2008. Senior management willhost a conference call and live audio webcast at 10:00 a.m. (ET) to discussthe results and recent activities.

DRAXIS Health, through its wholly owned operating subsidiary, DRAXISSpecialty Pharmaceuticals Inc., provides products in three categories: sterileproducts, non-sterile products and radiopharmaceuticals. Sterile productsinclude liquid and freeze-dried (lyophilized) injectables plus sterileointments and creams. Non-sterile products are produced as solid oral andsemi-solid dosage forms. Radiopharmaceuticals are used for both therapeuticand diagnostic molecular imaging applications. Pharmaceutical contractmanufacturing services are provided through the DRAXIS Pharma division andradiopharmaceuticals are developed, produced, and sold through the DRAXIMAGEdivision. DRAXIS employs approximately 500 staff in its Montreal facility.

This news release contains forward-looking statements within the meaningof Section 27A of the Securities Act of 1933, as amended (the "SecuritiesAct") and Section 21E of the Securities Exchange Act of 1934, as amended (the"Exchange Act") and as contemplated under other applicable securitieslegislation. These statements can be identified by the use of forward-lookingterminology such as "may," "will," "expect," "anticipate," "estimate,""continue," "plan," "intend," "believe" or other similar words. Thesestatements discuss future expectations concerning results of operations orfinancial condition or provide other forward-looking information. Our actualresults, performance or achievements could be significantly different from theresults expressed in, or implied by, those forward-looking statements. Youshould not place undue reliance on any forward-looking statement, which speaksonly as of the date made.

These statements are not guarantees of future performance. By theirnature, forward-looking statements involve numerous assumptions, known andunknown risks, uncertainties and other factors that may cause the actualresults or performance of the Company to be materially different from suchstatements or from any future results or performance implied thereby. Factorsthat could cause the Company's results or performance to differ materiallyfrom a conclusion, forecast or projection in the forward-looking statementsinclude, but are not limited to:

For additional information with respect to certain of these and otherfactors, and relating to the Company generally, reference is made to theCompany's most recent filings with the United States Securities and ExchangeCommission (available on EDGAR at www.sec.gov) and the filings made by theCompany with Canadian securities regulators (available on SEDAR atwww.sedar.com). The forward-looking statements contained in this new releaserepresent the Company's expectations as at February 6, 2008. Unless otherwiserequired by applicable securities laws, the Company disclaims any intention orobligation to update or revise any forward-looking statements, whether as aresult of new information, future events or otherwise.Details of the conference call and webcast are as follows: ------------------------------------------------------------------------- Date/time Thursday February 7, 2008 at 10:00 a.m. (ET) ------------------------------------------------------------------------- Dial-in number 1 (866) 321-6651 ACCESS CODE 8659140 and access code ------------------------------------------------------------------------- Audio webcast Access the live call on the DRAXIS web site at www.draxis.com The call will be archived on the web site for 30 days. ---------------------------------------------
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Kiadis Pharma Announces Successful Completion of R...
S
FDA Grants Priority Review for Schering-Plough's P...